Concord Biotech (BOM:543960) Cash And Cash Equivalents : ₹151 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Cash And Cash Equivalents?

Concord Biotech's quarterly cash and cash equivalents increased from Mar. 2023 (₹34.99 Mil) to Sep. 2023 (₹60.78 Mil) and increased from Sep. 2023 (₹60.78 Mil) to Mar. 2024 (₹151.42 Mil).

Concord Biotech's annual cash and cash equivalents increased from Mar. 2022 (₹6.67 Mil) to Mar. 2023 (₹34.99 Mil) and increased from Mar. 2023 (₹34.99 Mil) to Mar. 2024 (₹151.42 Mil).

Concord Biotech Cash And Cash Equivalents Historical Data

The historical data trend for Concord Biotech's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Cash And Cash Equivalents Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

24.08

51.44

6.67

34.99

151.42

Concord Biotech Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial			6.67	-	34.99	60.78	151.42

Concord Biotech Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Concord Biotech (BOM:543960) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Concord Biotech Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech (BOM:543960) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

CONCORDBIO:India

Address

Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines